MESS-study MRSA Eradication Study Skåne

This study is currently recruiting participants.
Verified June 2013 by Region Skane
Sponsor:
Information provided by (Responsible Party):
Region Skane
ClinicalTrials.gov Identifier:
NCT01269541
First received: January 3, 2011
Last updated: July 5, 2013
Last verified: June 2013
  Purpose

The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers


Condition Intervention
Throatcarriers of MRSA
Drug: Mupirocin
Drug: Rifampin+Clindamycine or Trimehoprimsulfa

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: MESS- MRSA Eradication Study Skåne. A Comparison Between Systemic Antibiotic Treatment in Combination With Topical Mupirocintreatment With Only Topical Mupiroicintreatment to Eradicate MRSA in Throat Carriers

Resource links provided by NLM:


Further study details as provided by Region Skane:

Primary Outcome Measures:
  • Culture for MRSA [ Time Frame: after 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 230
Study Start Date: March 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Mupirocin
Topical treatment
Drug: Mupirocin
Topical in the nose 3 times daily for 5 days
Drug: Rifampin+Clindamycine or Trimehoprimsulfa
Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
Active Comparator: Rifampicin+Clindamycine or Trimethoprimsulfa
Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2
Drug: Rifampin+Clindamycine or Trimehoprimsulfa
Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2

  Eligibility

Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for Rifampicin and Clindamycine or Trimethoprimsulfa -

Exclusion Criteria:

Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01269541

Contacts
Contact: Eva Melander, MD Phd +4640-33 74 86 eva.z.melander@skane.se
Contact: Anna-Karin Larsson, MD +464062950 anna-karin.a.larsson@skane.se

Locations
Sweden
Helsingborg hospital Recruiting
Helsingborg, Skåne, Sweden
Contact: Anna-Karin Larsson, MD       anna-karin.a.larsson@skane.se   
Principal Investigator: Anna-Karin Larsson, MD         
Kristianstad hospital Recruiting
Kristianstad, Skåne, Sweden
Contact: Henrik Elmrud, MD       henrik.elmrud@skane.se   
Principal Investigator: Henrik Elmrud, MD         
Infectious department SUS Lund Recruiting
Lund, Skåne, Sweden
Contact: Per Åkesson, MD Phd       per.akesson@skane.se   
Principal Investigator: Per Åkesson, MD Phd         
SUS Malmö Recruiting
Malmö, Skåne, Sweden
Contact: Anna Nilsson, MD PhD       anna.nilsson@med.lu.se   
Principal Investigator: Anna Nilsson, MD, PhD         
Karolinska university hospital Active, not recruiting
Stockholm, Sweden
Örebro university hospital Active, not recruiting
Örebro, Sweden
Sponsors and Collaborators
Region Skane
Investigators
Principal Investigator: Eva Melander, MD PHD Labmedicin Skåne Malmö
  More Information

No publications provided

Responsible Party: Region Skane
ClinicalTrials.gov Identifier: NCT01269541     History of Changes
Other Study ID Numbers: MRSA-2010, 2010-019727-55
Study First Received: January 3, 2011
Last Updated: July 5, 2013
Health Authority: sweden: Läkemedelsverket (Medical products agency)

Additional relevant MeSH terms:
Rifampin
Mupirocin
Trimethoprim-Sulfamethoxazole Combination
Antibiotics, Antitubercular
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Anti-Infective Agents, Urinary
Renal Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Protein Synthesis Inhibitors

ClinicalTrials.gov processed this record on April 20, 2014